Philippe Rogueda, PhD, Co-Founder and Chief Business Officer of Merxin, is a Fellow of the Royal Society of Chemistry and orally inhaled and nasal drug product expert with an accomplished track record delivering technology and global projects across R&D and commercial industrialisation. Dr Rogueda has held a number of positions in the inhaled drug delivery field, starting as a formulation scientist in the pMDI formulation labs of AstraZeneca; as a principal scientist at Novartis designing DPI, nasal and nebulised inhaled therapies; as an Executive Director of Inhaled Products R&D at Actavis/TEVA; before founding Merxin to make inhaler technology
accessible to a wider audience. Dr Rogueda is Principal Consultant at Aedestra, founder of the Inhalation Asia conference, and of Anthocan a company dedicated to the formulating of inhaled cannabis therapies.

More contributions